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Mean change from baseline to week 4 in serum K + and aldosterone were analyzed in 102 patients with NYHA classes I-III heart failure, and in 141 patients without heart failure. Patiromer starting doses were 8.4 g/day for patients with mild hyperkalemia (serum K + 5.1 to <5.5 mEq/L) and 16.8 g/day for patients with moderate-severe hyperkalemia (serum K + ≥5.5 mEq/L), divided twice daily.
RESULTS AND CONCLUSIONS
Baseline aldosterone was higher in patients with heart failure (Table) . In patients with mild hyperkalemia, small or nonsignificant changes in aldosterone were observed with modest serum K + reductions, regardless of heart failure status. In patients with moderate-severe hyperkalemia, significant decreases in aldosterone, which were greater in the heart failure subgroup, were observed with larger serum K + reductions (Table) . In conclusion, heart failure patients with moderate-severe hyperkalemia experienced the most improvement in aldosterone level with patiromer treatment. Serum K + may play an important role in modulating aldosterone in heart failure.
